This latest funding round brings Senda Biosciences’ total amount raised to $266 million. The funding will be used to finance clinical trials of Senda Biosciences’ programmable medicines platform, according to the Aug. 17 Senda Biosciences news release.
Along with the Mayo Clinic, Flagship Pioneering, Samsung Life Sciences Fund and Stage 1 Ventures also participated in the funding round.
“Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs,” Senda CEO Guillaume Pfefer, PhD, said. “We believe our approach could transform the lives of patients in need of novel treatments, and so we’re delighted to have attracted support from investors who recognize this potential and its significance.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.